You are here

Article Text

Article menu
Download PDFPDF
DTB Select
Which MAO-B inhibitor for Parkinson’s disease?

https://doi.org/10.1136/dtb.2018.000051

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Review of: Binde CD et al. A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson’s disease. Br J Clin Pharmacol 2018;84:1917–27.

    Key learning points

    • In the UK, three monoamine oxidase type B (MAO-B) inhibitors are licensed for the treatment of Parkinson’s disease.

    • There are no published trials that have directly compared all MAO-B inhibitors with each other.

    • The results of a meta-analysis suggest that selegiline may be superior when used in combination with levodopa.

    The authors of a meta-analysis suggest there is little to choose between monoamine oxidase type B (MAO-B) inhibitors as monotherapy for Parkinson’s disease, but selegiline may be superior when used in combination with levodopa.1

    Overview

    A meta-analysis (27 randomised trials; 7 578 participants) compared the relative efficacy of …

    View Full Text

    Footnotes

    • Provenance and peer review Commissioned; internally peer reviewed.

    • Contributors DTB Team.